When did Editas go public?
Sarah Cherry
Published Mar 20, 2026
When did Editas go public?
2 February 2016
it went public on 2 February 2016, with an IPO that raised $94 million.
Is Editas Medicine publicly traded?
Our common stock is traded on the NASDAQ Global Market under the ticker EDIT. Our initial public offering took place on February 3, 2016. Who were the managing underwriters for the Editas’ IPO? The underwriters for the IPO were Morgan Stanley, J.P. Morgan, Cowen and Company and JMP Securities.
Who invested in Editas?
Editas Medicine investors
| Date | Investors |
|---|---|
| Aug 2015 | GV Polaris Partners Fidelity Khosla Ventures Third Rock Ventures Casdin Capital Jennison Associates Omega Funds Deerfield Viking Global Investors Alexandria Venture Investments Flagship Pioneering Boris Nikolic EcoR1 Capital |
| Feb 2016 | GV |
| Jun 2020 | N/A |
| Jan 2021 | N/A |
When was Editas founded?
November 2013
Editas Medicine/Founded
Who owns Editas medicine?
ARK Investment Management LLC is currently the largest shareholder, with 13% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 9.4% and 8.5%, of the shares outstanding, respectively.
Is Editas a good stock to buy?
Editas Medicine has received a consensus rating of Hold. The company’s average rating score is 2.35, and is based on 9 buy ratings, 5 hold ratings, and 3 sell ratings.
Why is Editas stock up today?
Why Editas Medicine Stock Is Jumping Today The gain came after the company provided its third-quarter update earlier in the day. Editas reported revenue in the third quarter of $62.
Is Editas stock a good buy?
The financial health and growth prospects of EDIT, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
What Crispr company did Bill Gates invest in?
Intellia Therapeutics, an early entrant in the race to develop medicines using CRISPR gene editing, has won a grant from the Bill & Melinda Gates Foundation to fund research of an “in vivo” treatment for sickle cell disease using the Nobel Prize-winning technology.
Is Bill Gates invested in Crispr?
14, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV.
What kind of company is Editas medicine?
biotechnology company
Editas Medicine, Inc. operates as a biotechnology company. The Company offers transformative genome editing technology with the aim to translate the technology into a novel class of human therapeutics that enable precise and corrective molecular modification for the treatment of diseases.
How does Editas medicine work?
Our work on autologous cell medicines is focused on editing T cells, a type of immune cell, to improve their ability to detect and attack cancer cells in the body. Certain tumors are able to interfere with the activity of T cells by creating suppressive microenvironments.
